Fredag 27 December | 03:39:06 Europe / Stockholm

Prenumeration

Kalender

Tid*
2025-11-14 08:00 Kvartalsrapport 2025-Q3
2025-08-20 08:00 Kvartalsrapport 2025-Q2
2025-05-16 08:00 Kvartalsrapport 2025-Q1
2025-02-21 08:00 Bokslutskommuniké 2024
2024-11-15 - Kvartalsrapport 2024-Q3
2024-08-21 - Kvartalsrapport 2024-Q2
2024-05-24 - X-dag ordinarie utdelning PAX 0.00 SEK
2024-05-23 - Årsstämma
2024-05-23 - Kvartalsrapport 2024-Q1
2024-02-23 - Bokslutskommuniké 2023
2023-11-17 - Kvartalsrapport 2023-Q3
2023-08-24 - Kvartalsrapport 2023-Q2
2023-05-25 - X-dag ordinarie utdelning PAX 0.00 SEK
2023-05-24 - Årsstämma
2023-05-24 - Kvartalsrapport 2023-Q1
2023-02-24 - Bokslutskommuniké 2022
2022-11-18 - Kvartalsrapport 2022-Q3
2022-08-24 - Kvartalsrapport 2022-Q2
2022-05-27 - X-dag ordinarie utdelning PAX 0.00 SEK
2022-05-25 - Årsstämma
2022-05-25 - Kvartalsrapport 2022-Q1
2022-02-25 - Bokslutskommuniké 2021
2021-11-19 - Kvartalsrapport 2021-Q3
2021-08-27 - Kvartalsrapport 2021-Q2
2021-05-27 - X-dag ordinarie utdelning PAX 0.00 SEK
2021-05-26 - Årsstämma
2021-05-26 - Kvartalsrapport 2021-Q1
2021-02-26 - Bokslutskommuniké 2020
2020-11-20 - Kvartalsrapport 2020-Q3
2020-08-27 - Kvartalsrapport 2020-Q2
2020-05-28 - X-dag ordinarie utdelning PAX 0.00 SEK
2020-05-27 - Årsstämma
2020-05-27 - Kvartalsrapport 2020-Q1
2020-02-21 - Bokslutskommuniké 2019
2019-11-21 - Kvartalsrapport 2019-Q3
2019-08-29 - Kvartalsrapport 2019-Q2
2019-05-24 - X-dag ordinarie utdelning PAX 0.00 SEK
2019-05-23 - Årsstämma
2019-05-23 - Kvartalsrapport 2019-Q1
2019-02-27 - Bokslutskommuniké 2018
2018-11-22 - Kvartalsrapport 2018-Q3
2018-08-30 - Kvartalsrapport 2018-Q2
2018-05-25 - X-dag ordinarie utdelning PAX 0.00 SEK
2018-05-24 - Årsstämma
2018-05-24 - Kvartalsrapport 2018-Q1

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Paxman är verksamt inom skalpkylning, som används för patienter som behandlas för cytostatika. Bolagets produkt Paxman Scalp Cooler används för att minimera håravfallet hos patienten under behandlingens gång. Scalp Coolern är en fristående, mobil och eldriven kylenhet som kyler ner patientens hårbotten via en kylmössa. Paxman grundades 1996 och har idag sitt huvudkontor i Karlshamn.
2024-05-23 12:40:00

PAXMAN´s AGM was held today, 23 May 2024, at NetPort in Karlshamn. Almost 55,4 % of all issued shares were represented at the meeting. After the formal AGM, CEO Richard Paxman gave a company presentation and responded to questions from the attending shareholders.

In accordance with the proposal submitted by the Nomination Committee, the AGM resolved that the Board of Directors shall consist of seven Board Members without deputy members. The Board was re-elected in its entirety, and one person new elected. The board will consist of the following members up to the AGM 2025: Per-Anders Johansson (Chairman of the Board), Robert Kelly, Björn Littorin, Glenn Paxman, Richard Paxman, Maria Bech and Karen Giddings Clakely.

Also in accordance with the Nomination Committee’s proposal, the registered accountancy firm BDO Mälardalen AB was re-elected. BDO has notified that Niclas Nordström will remain chief auditor.

The Meeting further resolved that the total fees payable to the Board, excluding travel expenses, will be 550,000 SEK per annum, of which 150,000 SEK payable to the Chairman of the Board and 100,000 SEK to each of the Board Members elected by the AGM who are not employed by the company.

The Meeting finally resolved to approve the boards proposal to authorize the board to decide on a directed share issue involving an increase of the share capital by a maximum of SEK 1,901,250 through the issuance of a maximum of 1,901,250 new shares. The authorization entails a maximum total increase of the total number of shares in the Company by 10,0% (9,1% after the exercise of the authorization). The issue should be possible with deviation from the shareholders’ preferential rights. The authorization must be exercisable on one or more occasions at the latest until the next AGM, and the basis for the issue price for the exercise of the authorization shall be the market value of the share with or without consideration of market discount.

All resolutions made by the AGM were unanimous.